Literature DB >> 20029173

Vascular endothelial growth factor polymorphisms in mantle cell lymphoma.

S Galimberti1, B Nagy, G A Palumbo, E Ciancia, G Buda, E Orciuolo, A Melosi, P Lambelet, F Ronca, M Petrini.   

Abstract

In this study, we determined the allele and genotype frequencies of vascular endothelial growth factor (VEGF) G+405C, C-460T, C+936T and C-2578A single nucleotide polymorphisms (SNPs) in 32 patients affected by mantle cell lymphoma (MCL) and 58 healthy controls. Real-time PCR combined with melting curve analysis was used for the determination of SNP alleles. A significant difference in the allele frequency of VEGFC-460T and C+936T SNPs in MCL and healthy cases was not observed. On the contrary, VEGF G+405C and C-2578A SNP allele distribution was significantly lower in the patient group than among normal controls (p = 0.014, p = 0.001). This observation suggests that further investigation is warranted, both in vitro and in a larger series of patients, to further examine the role of VEGF polymorphisms in the pathogenesis of MCL. In addition, the use of quantitative real-time PCR combined with a melting curve analysis method in the detection of the 4 VEGF SNPs may have the potential to replace older and more time-consuming PCR-RFLP methods and bears further investigation. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20029173     DOI: 10.1159/000267826

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  7 in total

1.  Association of the vascular endothelial growth factor -2578C/A polymorphism with cancer risk: A meta-analysis update.

Authors:  Quanchi Chen; Zifei Zhou; Liangcheng Shan; Yingqi Hua; Hui Zeng; Pengcheng Liu; Zhengdong Cai
Journal:  Biomed Rep       Date:  2014-07-15

2.  Polymorphism of vascular endothelial growth factor -2578C/A with cancer risk: evidence from 11263 subjects.

Authors:  Chao Cao; Tao Ying; Jing-Jing Fang; Shi-Fang Sun; Dan Lv; Zhong-Bo Chen; Hong-Ying Ma; Yi-Ming Yu; Qun-Li Ding; Li-Hua Shu; Zai-Chun Deng
Journal:  Med Oncol       Date:  2010-07-16       Impact factor: 3.064

Review 3.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

4.  Polymorphism of VEGF-460C/T associated with the risk and clinical characteristics of lung cancer in Chinese population.

Authors:  Shi-Fang Sun; Da-Bing Huang; Chao Cao; Zai-Chun Deng
Journal:  Med Oncol       Date:  2013-01-04       Impact factor: 3.064

5.  Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.

Authors:  S Galimberti; M Petrini
Journal:  Cancer Manag Res       Date:  2010-06-28       Impact factor: 3.989

6.  VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma.

Authors:  Tomasz Wróbel; Grzegorz Mazur; Justyna Dzietczenia; Katarzyna Gębura; Kazimierz Kuliczkowski; Katarzyna Bogunia-Kubik
Journal:  Biomed Res Int       Date:  2013-08-26       Impact factor: 3.411

7.  Association of VEGFA-2578 C>A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients.

Authors:  G R A de Mendonça; A B C Brito; R M Rocha; M T Delamain; R de Andrade Natal; F A Soares; G W B Colleoni; C A Souza; J Vassallo; C S P Lima
Journal:  Blood Cancer J       Date:  2016-08-26       Impact factor: 11.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.